ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3	alectinib Resistant: C3 – Early Trials alectinib Resistant : C3
ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	crizotinib Resistant: C3 – Early Trials crizotinib Resistant : C3	crizotinib Resistant: C3 – Early Trials crizotinib Resistant : C3
ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	ALK inhibitor Resistant: C3 – Early Trials ALK inhibitor Resistant : C3	ALK inhibitor Resistant: C3 – Early Trials ALK inhibitor Resistant : C3
ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	ALK rearrangement + TP53 mutation	Non Small Cell Lung Cancer	alectinib + ixazomib Sensitive: D – Preclinical alectinib + ixazomib Sensitive : D	alectinib + ixazomib Sensitive: D – Preclinical alectinib + ixazomib Sensitive : D

ALK rearrangement + TP53 mutation

Associations